Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANVAC + Docetaxel in Metastatic Breast Cancer
NCT00179309Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- Feb 2013
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inalimarev and falimarev in breast cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-free Survival at 19.7 months. Started Sep 2005; status: completed.
02
Drugs
inalimarevfalimarev
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00179309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00179309.